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O R I G I N A L  A R T I C L E
ABSTRACT
Objective: To determine the frequency of peripheral neuropathy in newly diagnosed patients of Diabetes Mellitus type II on 
clinical and electrophysiological basis. Methods: This is Hospital based descriptive cross sectional study conducted at 
department of Neurology Civil Hospital Karachi/ Dow University of Health Sciences from 20th December 2011 to 20th June 
2012. Data was collected from Neurology OPD, Medicine OPD and Diabetic Clinic Civil Hospital Karachi. Results: Total no 
of patients were 107 who were already diagnosed as type 2 Diabetes Mellitus. Out of these, there were 57 (53.3%) male 
patients and 50 (46.7%) female patients, with ratio of males to female was . 1.14The age group distribution of study popu-
lation ranged from 30-60 years and mean age was 45.19 with standard deviation of 7.38. It was observed that 35 
(32.7%) patients had symptoms of peripheral neuropathy as compared to this 72 (67.3.2%) patients did not have symp-
toms of peripheral neuropathy  while mean ± standard deviation of duration of symptoms was 2.42±1.95 months and 18  
(16.8%) patients had peripheral neuropathy as compared to these 89 (83.2%) patients did not have peripheral neuropa-
thy, clinical or electrophysiological. Conclusion: Diabetic Peripheral Neuropathy is a fairly common entity in our patients 
with type 2 Diabetes Mellitus and was seen as early as within four weeks of diagnosis in 16.8% of patients.
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INTRODUCTION
Diabetes Mellitus is a syndrome with a disordered 
metabolism and inappropriate Hyperglycemia (1). Diabetes 
mellitus is the commonest endocrine disorder and one of 
the major health problems. More than 220 million people 
worldwide have diabetes (2). Pakistan alone currently 
counts 6.2 million people with diabetes and estimated 
figures for 2025 suggest that this will almost double and 
reaches 11.6 million people (3). Diabetes mellitus is classi-
fied on the basis of etiology and clinical presentation of 
the disorder into four types: type 1 diabetes, type 2 diabe-
tes, gestational diabetes and other specific types.  Type-2 
diabetes mellitus is the most prevalent form of diabetes (4). 
It results from a combination of insulin resistance and 
defective insulin secretion (4). Diabetes mellitus is associ-
ated with high-risk complications, essentially micro- and 
macro vascular complications (5). The micro vascular 
complications of diabetes mellitus, which include 
nephropathy, retinopathy, and neuropathy. Diabetic 
neuropathy is one of the most frequently encountered 
complications of diabetes mellitus (6,7). and commonest 
non-traumatic cause of limb amputation. The diabetic 
neuropathies are heterogeneous, affecting different parts 
of nervous system that present with diverse clinical mani-
festations. The pathogenesis for diabetic peripheral 
neuropathy is multifactorial. However Polyol pathway, 
advanced glycation end products and oxidative stress and 
chronic hyperglycaemia play important role.The DPN may 
be classifies as generalized symmetrical polyneuropathies 
and focal/multifocal neuropathies. The most common type 
of diabetic neuropathy is symmetrical, distal sensorimotor 
polyneuropathy (DPN) (8),which accounts for approximately 
75% of the diabetic neuropathies (9).  There is no local 
data available on the prevalence of peripheral neuropathy 
in diabetic patients at the time of diagnosis; however 
neuropathy is estimated to be present in 7.5% of patients 
at the time of diagnosis (10).The risk of developing sympto-
matic neuropathy in patients without neuropathic symp-
toms or signs at the time of initial diagnosis of diabetes is 
estimated to be 4% to 10% by 5 years and up to 50% by 
25 years (11). Diabetic neuropathy can manifest as combi-
nation of both positive (painful) like electrical sensation, 
squeezing, constricting, throbbing, freezing or knife like 
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and negative (no painful) symptom include asleep, dead, 
numbness or loss of touch or pain sensations. So the 
diagnosis of DPN can be made after careful clinical exami-
nation and excluding other commonforms of neuropathy 
like CIDP, vitamin B12 deficiency, hypothyroidism and 
uremia which can occur in diabetic patients by appropriate 
investigations. All the patients with diabetes should be 
screened for DPN at diagnosis of type 2 DM and 5 years 
after diagnosis of type 1 diabetes and at least annually by 
examining sensory functions in feet and checking ankle 
reflexes. In addition all have regular follow up for assess-
ment of glycemic control as well. Till date there are no 
reports from Pakistan regarding frequency of peripheral 
neuropathy in diabetic patients at the time of diagnosis. 
So this study is being carried out to see the frequency of 
Peripheral neuropathy at the time of diagnosis of type 2 
DM.
MATERIAL AND METHODS
This is Hospital based descriptive cross sectional study 
conducted at department of Neurology Civil Hospital 
Karachi/ Dow University of Health Sciences from 20th 
December 2011 to 20th June 2012. Data was collected 
from Neurology OPD, Medicine OPD and Diabetic clinic 
who were already diagnosed as Diabetes Mellitus type 2. 
The patient who fulfilled the selection criteria were 
enrolled in the study. Inclusion criteria were: the patients 
with age between 30-60 years, of either gender, 
diagnosed as cases of diabetes mellitus type2 within 
four weeks of presentation, that is, having Fasting Blood 
Sugar (FBS) of ≥ 126mg/dl, Random Blood Sugar 
(RBS) of ≥ 200mg/dl or HbA1c≤ 6.5 along with no 
previous history of testing positive for diabetes mellitus 
or taking any treatment for diabetes.Exclusion criteria 
included  patient’s  having peripheral neuropathy due to 
other causes i.e. hereditary (ruled out by simply assess-
ing that at 30 years patients were past the age of onset 
of most of the common hereditary neuropathies22 and 
absence of family history; no genetic studies done), 
autoimmune (acute/chronicinflammatory demyelinating 
polyneuropathy), drugs and patients with systemic 
illnesses like chronic renal failure, hypothyroidism, 
Vit.B12 deficiency, liver disease, vasculitis,leprosy, or 
malignancy. Informed consent was obtained from all the 
patients after explanation of the study protocol. The data 
was collected on proforma (annexed) wasspecially 
developed for the study. Patients who were included in 
the study all underwent first clinical examination and 
then Nerve Conduction Studies and also Electromyogra-
phy where necessary.
Nerve conduction studies protocol included 
Testing most involved limb first. 
Testing at least 2 limbs (i.e. one upper and one lower) 
and  3rd limb for symmetry.
In the lower extremity, we examined:
Sural sensory.
Peroneal motor with conduction.
Tibial motor.
Tibial F-response.
In the upper extremity, we examined:
Two sensory nerves, mostly median or ulnar.
Two motor nerves mostly median or ulnar.
An F-response (either median or ulnar).
Examination of additional nerves if needed to differenti-
ate between axonal or demyelinating types. 
Electromyography was done if required only and the 
protocol included:
Examining a distal muscle, including an intrinsic foot 
muscle.
At least three muscles were sampled from each extrem-
ity, of which at one was a proximal muscle. 
Other muscles were tested to confirm an impression of 
neuropathy based on nerves, when required.
Any abnormalities were confirmed by examination of at 
least one contralateral muscle to ascertain symmetry.
Skin punch biopsy for small fiber neuropathy was 
not done and so also formal testing for autonomic 
function.
 
After confirmation of presence of neuropathy, these 
patients were further investigated to rule out other possi-
ble causes that could have led to the same clinical situa-
tion. For that purpose all these patients were investigated 
for HbA1c, Vit B12 deficiency, hypothyroidism, chronic 
renal failure, vasculits, whenever clinically indicated other 
investigation like ANA were also performed and patients 
accordingly included or excluded. Data was analyzed on 
SPSS 17 and results were formulated accordingly.  
RESULTS
Total no of 20,000 patients attending different OPDs in 
CHK were interviewed. Of these one hundred and seven 
patients attending Diabetic clinic, Medicine OPD and 
Neurology OPD in Civil Hospital Karachi were found to 
have recently diagnosed DM, i.e., they presented within 
four weeks of diagnosis were selected for  further evalua-
tion.  These were initially evaluated by History and Neuro-
logical examination for diabetic peripheral neuropathy 
followed by Nerve conduction studies to establish the 
presence of peripheral neuropathy. Out of 107 patients, 
there were 57 (53.3%) male patients and 50 (46.7%) 
female patients and male to female ratio was 1.14 (Table 
01). The age of study population ranged from 30-60 
years. Mean age of the patients were 45.19 years (Table 
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02). Majority of patients 45 (42.1%) who were 
diagnosed as a case of Diabetic peripheral neuropathy 
were in 5th decade (41-50 years). 33 (30.8%) were in 
4th decade (31-40 years) and 29 (27.1%) were in 6th 
decade (51-60 years) It was observed that 35 (32.7%) 
patients had symptoms of peripheral neuropathy at the 
time of presentation as compared to 72 (67.3.2%) 
patients who did not. (Table 03). Duration of symptoms 
in 15 (29.4%) patients was less than I month, in 20 
(39.2%) between 1-3 months and in 16 (31.4%) 
between 4-7 months while mean ± standard deviation of 
duration of symptoms was 2.42±1.95 months (Table 
04). When we checked the stratification of duration of 
symptoms by using Chi-square test we got a P. Value 
(0.609) is greater than α level (.05), so we concluded 
that there was no significant difference on the basis of 
duration of symptoms. On NCVs 18 (16.8%) patients 
had peripheral neuropathy as compared to these 89 
(83.2%) patients did not have peripheral neuropathy on 
(Table 05) On further analysis of patients having periph-
eral neuropathy 5 (27.8%) having symptoms 13 (72.2%) 
having no symptoms (Table 06). While patients having no 
peripheral neuropathy 30 (33.7%) were symptomatic 
and 59 (66.3%) have no symptoms (Table 07).
Table 01: Gender Analysis
Table 02: Age Group distribution of study population
 
Table 03: Symptoms presentation of study population
Table 04: Analysis of Duration of Symptoms
Table 05: Analysis of frequency of Peripheral Neuropathy
Table 06: Peripheral Neuropathy Yes and Symptoms
Table 07: Peripheral Neuropathy No and Symptoms
DISCUSSION
The diabetic neuropathies are heterogeneous, affecting 
different parts of nervous system that present with diverse 
clinical manifestations. DPN considered in some respect to be 
a "Cinderella" of microvascular complication of diabetes, receiv-
ing less attention than it deserve with  regard to screening, early 
detection, treatment and prevention. Diabetic peripheral 
neuropathy is one of the commonest complications of diabetes 
mellitus and it may be the first presenting symptom in type 2 
diabetes. Patients with diabetes mellitus can develop nerve 
complications at any time, but longer the duration, greater the 
risk. An estimated 50% of those with diabetes have some form 
of neuropathy, but not all with neuropathy have symptoms (12). 
The prevalence of peripheral neuropathy in diabetic patients at 
the time of diagnosis is estimated to be present in 7.5% of 
patients at the time of diagnosis (10). This reported prevalence of 
diabetic neuropathy varies from less (16) and Pirart(17) observed 
a lower prevalence of diabetic peripheral neuropathy in 6.3% 
and 7% respectively in their studies. Weerasuriya et al (18) 
observed 9.8 % of their diabetics had evidence of diabetic 
neuropathy at the time of diagnosis in their study from Sri 
Lanka. Ashok and his colleagues(19) observed a prevalence of 
neuropathy in 5.4% of their patients with type 2 diabetes at the 
time of diagnosis. These differences in the prevalence of 
peripheral diabetic neuropathy among different studies and our 
can be explained because our study used clinical and electro-
physiological studies, whereas neuropathy assessed by others 
and Ashok et al(19) used a biothesiometer, which is compara-
tively a less sensitive method for detection of peripheral 
neuropathy. However a reason for the higher no of patients 
having neuropathy at the time of diagnosis of DM in our 
patients may be due to delay in diagnosis of condition, due to 
lack of awareness and financial resources. Ather N A, et al. 
reported in their study age ranged from 39-90 years with mean 
(58±11.2) years with peripheral neuropathy (20). In our study 
age ranged 30-60 years with mean age of patients was 
45.1±7.38 years. In our study 11 (61.1%) were male, 7 
(38.9%) were female out of 18 (16.8%) (p=0.465). However, 
Ather et al in their study with peripheral neuropathy showed 36 
(20.3%) male and 57 (51.4%) were female out of 159 
(53.0%). In addition ArindamDutta et al (15) in their study 
Gender  Frequency Percent
Male  57  53.3%
Female  50  46.7%
Total  107  100.0%
Age Groups Frequency Percent Mean Std. Deviation
31-40 Years 33 30.8%  
41-50 Years 45 42.1% 45.19 7.38
51-60 Years 29 27.1% 
Symptoms Frequency Percent
Yes  35  32.7%
No  72  67.3%
Duration of
Symptom Frequency Percent Mean±SD
<1 Months 15 29.4% 
   2.42±1.95
1-3 Months 20 39.2% 
4-7 Months 16 31.4% 
Peripheral Neuropathy Frequency Percent
Yes   18  16.8%
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showed that in 29 patients who diagnosed of peripheral 
neuropathy in which 17 (28%) were males and 12 (31%) 
females out of the 100 newly diagnosed type 2 diabetic 
patients had peripheral neuropathy and females were affected 
more than the males (31:28) although it is not statistically 
significant, but in our study male were more affected. Nerve 
conduction studies detect neuropathy not only at an earlier 
stage but are also higly specific and sensitive tool. Bao XM et al 
reported in their study that 7.1% had symptoms while 9.8% 
had neuropathy confirmed by nerve conduction studies (21). This 
shows that symptoms and signs of neuropathy are less reliable 
marker of diabetic neuropathy than NCS. So nerve conduction 
studies should be advised as important diagnostic tool for early 
detection of diabetic peripheral neuropathy in every diabetic 
patient. In our study we could not assess glycemic state of the 
patient at the time of diagnosis, so as to ascertain if higher 
glucose levels at diagnosis are associated with early onset of 
peripheral neuropathy, as is commonly assumed or not. There 
may be other unidentified factors involved in addition to higher 
glucose levels. Nevertheless, this study provides new data from 
Pakistan regarding newly diagnosed diabetic peripheral 
neuropathy and needs further research regarding early detec-
tion of diabetic peripheral neuropathy. However lack of consist-
ent criteria for the diagnosis of diabetic neuropathy, variability in 
case selection and different techniques of assessment make it 
difficult to establish case of diabetic neuropathy uniformly 
across different centers even in a same region I strongly 
suggest that with the help of different diabetic associations in 
our country, we must develop diagnostic criteria for diabetic 
peripheral neuropathy at least for local and regional use. In 
addition suggested biochemical changes take time to cause 
Diabetic Peripheral Neuropathy but for early development of 
neuropathy there might be another explanation which needs to 
be evaluated. 
CONCLUSION
Diabetic Peripheral Neuropathy is a fairly common entity 
in our patients with type 2 DM and was seen as early as 
within four weeks of diagnosis in 16.8% of patients. It is 
necessary to search for this potentially painful and 
disabling complication of Diabetes Mellitus in all patients 
at the time of diagnosis and also at periodic intervals.
INFERENTIAL STATISTICS
Table No 08: Peripheral Neuropathy cross tab by Age Groups
  
As P. Value (0.036) is less than α level (.05), so we conclude that there is significance difference on the basis of age
groups. 
Table No 09: Peripheral Neuropathy cross tab by Gender
As P. Value (0.465) is greater than α level (.05), so we conclude that there is no any significance difference on the
basis of gender. 
Table No 10: Peripheral Neuropathy cross tab by Duration of Symptom
As P. Value (0.609) is greater than α level (.05), so we conclude that there is no any significance difference on the
basis of duration of symptoms
  Age Groups
  31-40 Years 41-50 Years 51-60 Years
  n % N % N % P Value
Peripheral 
Neuropathy Yes 1 5.6% 11 61.1% 6 33.3% 0.036
 No 32 36.0% 34 38.2% 23 25.8%
  Duration of Symptom  
    <1 Months 1-3 Months 4-7 Months 
    n % N % N % P Value
Peripheral
Neuropathy Yes 4 22.2% 7 38.9% 7 38.9% 0.609
  No 11 33.3% 13 39.4% 9 27.3%
  Gender  
    Male  Female 
    n % N % P Value
Peripheral
Neuropathy Yes 11 61.1% 7 38.9% 0.465
  No 46 51.7% 43 48.3% 
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